Association Between RBC Antigen Allo-Antibodies and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Treatment for Advanced Cancers.

Natasha A JainSongzhu ZhaoLai Wei Kerry A RogersGregory A OttersonTzu-Fei Wang Dwight H Owen

Published in: Cancer management and research (2020)

Given the increasing use of ICI, oncologists should be aware of potential irAEs with ICI. We found an association between the presence of an alloAb pre-ICI and the development of irAE, indicating that this previous non-self antigen response may predict immune adverse events. A larger prospective study is needed for systematic evaluation of the association between alloAb testing and irAE, and whether routine testing may inform clinical decision-making for patients.

Keyphrases

decision making
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
clinical practice
patient reported outcomes
risk assessment
young adults
palliative care
human health
drug induced